- SOHM is launching a line of 13 new chewables that offer a range of health benefits and expand the company’s preventative care product portfolio
- The new line will be available online through Amazon.com and the company’s direct-to-consumer website and will be showcased at industry conferences in 2024
- SOHM is addressing its increased product demand by establishing a new CDMO GMP manufacturing facility in Carlsbad, California
- The new manufacturing facility is expected to be open by the end of 2023, and shareholders will be updated about its operations during its year-end 2023 report
SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, recently announced the launch of new products to the company's catalog and expansion into a new CDMO GMP manufacturing facility in Carlsbad, California.
SOHM is set to enter the global vitamin gummies market by launching 13 new SOHM Nutrients Brand Chewables. The global vitamins market, valued at $6.84 billion in 2022, is expected to reach $18.76 billion by 2031, driven...
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at http://ibn.fm/SHMN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN